NCT07624305ClinicalTrials.gov
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)
In brief
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…
Phase 32,800 participants sought478 sites27 countries
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07624305Open this record at ClinicalTrials.govSynced 2 months ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.
How this score is built
- Enrolment34/40
2,800 participants (target)
- Site count19/25
45 sites
- Country count12/15
8 countries
- Planned duration9/10
Planned over about 47 months
- Sponsor scale10/10
AstraZeneca has led 999 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.
Conditions
- Renal Insufficiency, Chronic
Eligibility
| Sex | All |
|---|---|
| Ages | 18 Years – 99 Years |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 3 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 2,800 participants sought |
Sponsor and collaborators
- AstraZeneca Sponsor
Arms and interventions
- Balcinrenone/dapagliflozinEXPERIMENTAL
Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.
- DapagliflozinACTIVE_COMPARATOR
Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.
Interventions
- Drug Balcinrenone/dapagliflozin
balcinrenone/dapagliflozin 15 mg/10 mg
- Drug Dapagliflozin
dapagliflozin 10 mg
- Drug Placebo matching Dapagliflozin
matching placebo for dapagliflozin 10 mg
- Drug Placebo matching balcinrenone/dapagliflozin
matching placebo for balcinrenone/dapagliflozin
Outcome measures
Primary outcome
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation
Time frame Up to 46 months.
Secondary outcome
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR
Time frame Up to 46 months.
Secondary outcome
Change in urinary albumin to creatinine ratio to Week 24
Change from baseline to Week 24 in urinary albumin to creatinine ratio
Time frame Baseline to Week 24
Secondary outcome
Time to first occurrence of cardiovascular death or heart failure event.
Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation
Time frame Up to 46 months.
Secondary outcome
Time to cardiovascular death
Time from randomization to cardiovascular death.
Time frame Up to 46 months.
Secondary outcome
Time to death from any cause
Time from randomization to death from any cause.
Time frame Up to 46 months.
Dates
| Start date | September 1, 2026 (actual) |
|---|---|
| Primary completion | July 1, 2030 (estimated) |
| Completion | July 1, 2030 (estimated) |
| First posted | June 3, 2026 (actual) |
| Last updated | September 24, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | September 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
33 sites are recruiting
Argentina
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | CABA | Not yet recruiting | |
| Research Site | Capital Federal | Not yet recruiting | |
| Research Site | Ciudad de Buenos Aires | Not yet recruiting | |
| Research Site | La Plata | Not yet recruiting | |
| Research Site | Lanús Este | Not yet recruiting | |
| Research Site | Mar del Plata | Not yet recruiting | |
| Research Site | Rosario | Not yet recruiting | |
| Research Site | Rosario | Not yet recruiting | |
| Research Site | Rosario | Not yet recruiting | |
| Research Site | San Nicolás | Not yet recruiting | |
| Research Site | Santa Fe | Not yet recruiting | |
| Research Site | Santa Fe | Not yet recruiting |
Austria
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Feldkirch | Not yet recruiting | |
| Research Site | Innsbruck | Not yet recruiting | |
| Research Site | Linz | Not yet recruiting | |
| Research Site | Sankt Pölten | Not yet recruiting | |
| Research Site | Vienna | Not yet recruiting | |
| Research Site | Vienna | Not yet recruiting | |
| Research Site | Vienna | Not yet recruiting | |
| Research Site | Vienna | Not yet recruiting | |
| Research Site | Wels | Not yet recruiting | |
| Research Site | Wiener Neustadt | Not yet recruiting |
Brazil
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Barretos | Not yet recruiting | |
| Research Site | Belo Horizonte | Not yet recruiting | |
| Research Site | Belo Horizonte | Not yet recruiting | |
| Research Site | Belém | Not yet recruiting | |
| Research Site | Campinas | Not yet recruiting | |
| Research Site | Goiânia | Not yet recruiting | |
| Research Site | Natal | Not yet recruiting | |
| Research Site | Recife | Not yet recruiting | |
| Research Site | São Caetano do Sul | Not yet recruiting | |
| Research Site | São José do Rio Preto | Not yet recruiting | |
| Research Site | São José dos Campos | Not yet recruiting | |
| Research Site | São Paulo | Not yet recruiting | |
| Research Site | São Paulo | Not yet recruiting | |
| Research Site | São Paulo | Not yet recruiting | |
| Research Site | São Paulo | Not yet recruiting |
Bulgaria
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Blagoevgrad | Not yet recruiting | |
| Research Site | Nova Zagora | Not yet recruiting | |
| Research Site | Pleven | Not yet recruiting | |
| Research Site | Plovdiv | Not yet recruiting | |
| Research Site | Sandanski | Not yet recruiting | |
| Research Site | Sevlievo | Not yet recruiting | |
| Research Site | Sofia | Not yet recruiting | |
| Research Site | Sofia | Not yet recruiting | |
| Research Site | Sofia | Not yet recruiting | |
| Research Site | Stara Zagora | Not yet recruiting | |
| Research Site | Varna | Not yet recruiting |
Canada
| Facility | City | State or region | Status |
|---|---|---|---|
| Research Site | Brampton | Ontario | Not yet recruiting |
| Research Site | Calgary | Alberta | Withdrawn |
428 further sites are listed in the registry record.
Study documents
No documents are linked in this registry record.
Changes over time
- September 24, 2026
Status changed
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- September 24, 2026
Recruitment opened
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- September 24, 2026
Site added
433 sites added (478 total)
45478